Drug Class: DPP-4 Inhibitor + Biguanide Antidiabetic Combination | Form: Extended-Release Oral Tablet | Prescription Status: Prescription Only (Rx) — DRAP Registered
What is Sita-Met XR 50/1000mg Tablet? Sita-Met XR 50/1000mg contains Sitagliptin 50mg and Metformin Hydrochloride 1000mg in an extended-release formulation — a dose-adjusted combination specifically designed for patients with moderate kidney impairment where the standard 100mg Sitagliptin dose accumulates unsafely, combined with the maximum therapeutic Metformin dose for patients tolerating higher Metformin exposure. The XR mechanism releases Metformin gradually over several hours — significantly reducing the gastrointestinal side effects of nausea, cramping, and diarrhoea that commonly cause early treatment discontinuation with immediate-release Metformin at the 1000mg dose. Sitagliptin 50mg provides meaningful DPP-4 inhibition appropriate for reduced kidney clearance while Metformin 1000mg delivers its strongest hepatic glucose suppression and peripheral insulin sensitisation — together providing comprehensive dual-pathway blood sugar control in a single convenient tablet.
What is Sita-Met XR 50/1000mg Used For?
- Type 2 diabetes with moderate kidney impairment — dose-adjusted Sitagliptin with maximum Metformin (گردوں کی اعتدالی کمزوری میں ذیابیطس ٹائپ 2 کا علاج)
- Type 2 diabetes requiring stronger Metformin coverage with adjusted Sitagliptin dose
- Step-up from Sita-Met XR 50/500mg — uptitrating Metformin to 1000mg while maintaining dose-adjusted Sitagliptin
- Established dual antidiabetic therapy — replacing separate Sitagliptin 50mg and Metformin XR 1000mg tablets (علیحدہ دوائیں ایک گولی میں یکجا کرنا)
- Type 2 diabetes with significant insulin resistance — maximum Metformin dose maximises insulin sensitising benefit (شدید انسولین مزاحمت میں علاج)
- Overweight Type 2 diabetic patients with moderate renal impairment — Metformin weight-neutral benefit
How Does it Work? Sitagliptin 50mg selectively inhibits DPP-4 enzyme — preventing breakdown of GLP-1 and GIP incretin hormones to maintain elevated active incretin levels that stimulate glucose-dependent insulin secretion and suppress glucagon from pancreatic cells. At 50mg this DPP-4 inhibition remains clinically meaningful — providing effective postprandial glucose control while maintaining safe drug exposure in patients with reduced kidney clearance. Metformin 1000mg delivers maximum hepatic action — strongly inhibiting gluconeogenesis and glycogenolysis to produce the greatest reduction in fasting hepatic glucose output. It simultaneously maximises peripheral insulin sensitisation in muscle and adipose tissue and reduces intestinal glucose absorption. The XR mechanism distributes 1000mg Metformin absorption gradually — achieving equivalent glycaemic efficacy to immediate-release 1000mg while substantially reducing the gastrointestinal side effects that limit tolerability at this higher dose.
Dosage and Administration
⚠️ Swallow whole — never crush, break, or chew the extended-release tablet. Take with evening meal for best tolerability and absorption. Stop before any iodinated contrast imaging — lactic acidosis risk amplified at 1000mg Metformin. Monitor kidney function regularly — dose-adjusted Sitagliptin 50mg appropriate for GFR 30 to 50ml/min; below 30ml/min requires further Sitagliptin reduction. Never exceed total daily Metformin 2000mg from all sources.
| Indication | Usual Adult Dose | Frequency | Notes |
|---|---|---|---|
| Type 2 diabetes — moderate renal impairment | 50mg/1000mg | Once or twice daily with meals | GFR 30 to 50ml/min for Sitagliptin dose |
| Step-up from 50/500mg | 50mg/1000mg | Twice daily with meals | After tolerability confirmed at lower Metformin dose |
| Established combination therapy | 50mg/1000mg | Twice daily with meals | Replacing separate tablets |
Active Ingredients
| Ingredient | Strength |
|---|---|
| Sitagliptin Phosphate Monohydrate | 50mg (as Sitagliptin) |
| Metformin Hydrochloride | 1000mg (Extended-Release) |
Who Should NOT Take Sita-Met XR 50/1000mg?
- Allergy to Sitagliptin, Metformin, or any component of the tablet
- Type 1 diabetes mellitus — not indicated
- Diabetic ketoacidosis — requires urgent insulin therapy
- Severe kidney impairment — GFR below 30ml/min; Metformin 1000mg contraindicated and Sitagliptin requires further reduction to 25mg
- Moderate kidney impairment where Metformin is also contraindicated — GFR below 45ml/min for Metformin
- Severe liver impairment — Metformin lactic acidosis risk significantly elevated
- Acute conditions causing dehydration or tissue hypoxia — heart failure, respiratory failure, recent myocardial infarction, sepsis
- History of pancreatitis — Sitagliptin associated with increased pancreatitis risk
- Alcohol dependence — amplifies lactic acidosis risk at maximum Metformin dose
- Planned iodinated contrast imaging — stop before procedure
- Pregnancy and breastfeeding — insulin preferred
- Children under 18 years
Side Effects
Common: Mild nausea, mild stomach discomfort, mild diarrhoea — substantially reduced by XR formulation even at maximum 1000mg Metformin dose; taking with evening meal further minimises gastrointestinal effects. Mild headache, mild upper respiratory symptoms — generally well tolerated.
Serious — Stop and seek emergency help immediately: Lactic acidosis — most critical risk at maximum Metformin dose in renally impaired patients; severe muscle pain, extreme difficulty breathing, severe abdominal pain, profound weakness, feeling cold, slow or irregular heartbeat (فوری ہسپتال جائیں — یہ سب سے خطرناک طبی ہنگامی صورتحال ہے — ایک لمحہ بھی دیر نہ کریں), acute pancreatitis — severe persistent upper abdominal pain radiating to back (پیٹ میں شدید درد — فوری مدد لیں), severe allergic reaction — swelling of face or throat with breathing difficulty (فوری ہسپتال جائیں), Stevens-Johnson syndrome — widespread blistering and peeling skin (فوری مدد لیں), significant disabling joint pain — severe arthralgia (جوڑوں کا شدید درد — ڈاکٹر کو بتائیں), worsening heart failure — breathlessness with severe ankle swelling (فوری مدد لیں), hypoglycaemia when combined with sulphonylurea or insulin (بلڈ شوگر کا گرنا — فوری میٹھا کھائیں).
Drug Interactions
| Medicine | Interaction |
|---|---|
| Iodinated contrast media | Stop minimum 48 hours before any contrast procedure — lactic acidosis risk maximally amplified at 1000mg Metformin in renally impaired patients; restart only after kidney function confirmed normal |
| Sulphonylureas (Glibenclamide, Glimepiride) | Significantly increased hypoglycaemia risk — sulphonylurea dose reduction typically required |
| Insulin | Increased hypoglycaemia risk — careful insulin dose adjustment under specialist supervision |
| Alcohol (شراب) | Maximally increases lactic acidosis risk — particularly dangerous at 1000mg Metformin in patients with reduced kidney function; avoid completely |
| Corticosteroids (Prednisolone) | Significantly raise blood glucose — both components less effective; monitor very closely |
| Diuretics (Furosemide, Thiazides) | Dehydration increases lactic acidosis risk — most significant at maximum Metformin dose in renally impaired patients |
| ACE inhibitors / ARBs | May cause acute kidney deterioration — Metformin 1000mg accumulates most rapidly with any renal decline in already impaired kidneys |
| Cimetidine | Significantly increases Metformin blood levels — lactic acidosis risk amplified in kidney impairment |
| Beta-blockers | Mask hypoglycaemia warning signs — particularly important when combined with sulphonylurea or insulin |
| Topiramate / Carbonic anhydrase inhibitors | Increased lactic acidosis risk — avoid combination especially in kidney impairment |
Storage: Store below 25°C in a cool, dry place. Protect from moisture and direct sunlight. Swallow whole — never break, crush, or chew. Keep out of reach of children (بچوں کی پہنچ سے دور رکھیں). Do not use after expiry date.
FAQs
Q: Why does Sita-Met XR 50/1000mg contain 50mg Sitagliptin rather than the standard 100mg when Metformin is at its maximum 1000mg dose? The 50mg Sitagliptin dose reflects kidney function-based dose adjustment — Sitagliptin is primarily renally excreted and accumulates at standard 100mg doses when GFR is between 30 and 50ml/min. Metformin 1000mg is compatible with this renal function range for most patients — so the combination of dose-adjusted 50mg Sitagliptin with maximum-efficacy 1000mg Metformin provides optimal dual glycaemic control while maintaining Sitagliptin safety at the patient's kidney function level.
Q: Why is lactic acidosis risk particularly important for patients taking Sita-Met XR 50/1000mg? Patients already taking the dose-adjusted 50mg Sitagliptin have some degree of kidney impairment — reduced kidney function means Metformin 1000mg clearance is also reduced compared to patients with normal kidneys. Any further acute kidney deterioration from illness, dehydration, contrast media, or certain medicines can cause rapid dangerous Metformin accumulation. This population requires more vigilant kidney function monitoring and more conservative clinical precautions than patients taking the same Metformin dose with normal kidney function.
Q: What should a patient do if they develop acute illness — vomiting, diarrhoea, or fever — while taking Sita-Met XR 50/1000mg? Acute illness causing dehydration significantly impairs kidney function temporarily — in a patient already on dose-adjusted therapy this can trigger dangerous Metformin accumulation and lactic acidosis risk. Sita-Met XR should be temporarily stopped during acute illness with dehydration, reduced fluid intake, or fever until the illness resolves and normal oral intake resumes. Always consult your diabetologist for specific sick-day management guidelines — never attempt to manage this independently.
Medical Disclaimer: This information is for general awareness only and does not replace medical advice. Always consult a qualified doctor or pharmacist before taking any prescription medicine.